Moxifloxacin (oral)

Moxifloxacin (oral)

Clinical data
Pregnancy category	C (US) B3 (Australia)
Routes of administration	Oral, IV, local (eyedrops)
ATC code	J01MA14 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	86 to 92%
Protein binding	30 to 50%
Metabolism	Glucuronide and sulfate conjugation Cytochrome P450 system not involved
Elimination half-life	12 hours
Excretion	Biliary and renal
Identifiers
IUPAC name 1-cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo [4.3.0]non-8-yl]-6-fluoro-8-methoxy-4-oxo- quinoline-3-carboxylic acid
CAS Number	354812-41-2
PubChem CID	152946
DrugBank	APRD00281
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H24FN3O4
Molar mass	401.431 g/mol

WikiDoc Resources for Moxifloxacin (oral)
Articles
Most recent articles on Moxifloxacin (oral) Most cited articles on Moxifloxacin (oral) Review articles on Moxifloxacin (oral) Articles on Moxifloxacin (oral) in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Moxifloxacin (oral) Images of Moxifloxacin (oral) Photos of Moxifloxacin (oral) Podcasts & MP3s on Moxifloxacin (oral) Videos on Moxifloxacin (oral)
Evidence Based Medicine
Cochrane Collaboration on Moxifloxacin (oral) Bandolier on Moxifloxacin (oral) TRIP on Moxifloxacin (oral)
Clinical Trials
Ongoing Trials on Moxifloxacin (oral) at Clinical Trials.gov Trial results on Moxifloxacin (oral) Clinical Trials on Moxifloxacin (oral) at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Moxifloxacin (oral) NICE Guidance on Moxifloxacin (oral) NHS PRODIGY Guidance FDA on Moxifloxacin (oral) CDC on Moxifloxacin (oral)
Books
Books on Moxifloxacin (oral)
News
Moxifloxacin (oral) in the news Be alerted to news on Moxifloxacin (oral) News trends on Moxifloxacin (oral)
Commentary
Blogs on Moxifloxacin (oral)
Definitions
Definitions of Moxifloxacin (oral)
Patient Resources / Community
Patient resources on Moxifloxacin (oral) Discussion groups on Moxifloxacin (oral) Patient Handouts on Moxifloxacin (oral) Directions to Hospitals Treating Moxifloxacin (oral) Risk calculators and risk factors for Moxifloxacin (oral)
Healthcare Provider Resources
Symptoms of Moxifloxacin (oral) Causes & Risk Factors for Moxifloxacin (oral) Diagnostic studies for Moxifloxacin (oral) Treatment of Moxifloxacin (oral)
Continuing Medical Education (CME)
CME Programs on Moxifloxacin (oral)
International
Moxifloxacin (oral) en Espanol Moxifloxacin (oral) en Francais
Business
Moxifloxacin (oral) in the Marketplace Patents on Moxifloxacin (oral)
Experimental / Informatics
List of terms related to Moxifloxacin (oral)

Moxifloxacin
AVELOX® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Overview

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox® (in some countries also Avalox®) for oral treatment. Each tablet contains 400 mg. In most countries the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the name Vigamox® for the treatment of conjunctivitis.

Category

Fluoroquinolone, fourth generation.

US Brand Names

AVELOX®, MOXEZA®, VIGAMOX®.

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21277slr018,21085slr023_avelox_lbl.pdf